Literature DB >> 21933305

Leishmaniasis impact and treatment access.

M den Boer1, D Argaw, J Jannin, J Alvar.   

Abstract

According to disease burden estimates, leishmaniasis ranks third in disease burden in disability-adjusted life years caused by neglected tropical diseases and is the second cause of parasite-related deaths after malaria; but for a variety of reasons, it is not receiving the attention that would be justified seeing its importance. This is especially apparent in the unnecessarily and unacceptably poor access to timely and appropriate treatment for patients. To our knowledge, this is the first publication that addresses the major issues associated with poor access to drugs for leishmaniasis and that outlines a number of feasible and practical solutions.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21933305     DOI: 10.1111/j.1469-0691.2011.03635.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  75 in total

Review 1.  Leishmaniasis in the United States: treatment in 2012.

Authors:  Henry W Murray
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

2.  Neglected tropical diseases: operational research for elimination and control.

Authors:  Johan van Griensven
Journal:  Public Health Action       Date:  2012-09-21

3.  Immunomodulatory and Antileishmanial Activity of Phenylpropanoid Dimers Isolated from Nectandra leucantha.

Authors:  Thais Alves da Costa-Silva; Simone S Grecco; Fernanda S de Sousa; João Henrique G Lago; Euder G A Martins; César A Terrazas; Sanjay Varikuti; Katherine L Owens; Stephen M Beverley; Abhay R Satoskar; Andre G Tempone
Journal:  J Nat Prod       Date:  2015-04-02       Impact factor: 4.050

4.  Spectroscopic Study of the Interactions of Ruthenium-Ketoconazole Complexes of Known Antiparasitic Activity with Human Serum Albumin and Apotransferrin.

Authors:  Jesús G Estrada; Roberto A Sánchez-Delgado
Journal:  J Mex Chem Soc       Date:  2013       Impact factor: 0.524

5.  Metal-drug synergy: new ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cells.

Authors:  Eva Iniguez; Antonio Sánchez; Miguel A Vasquez; Alberto Martínez; Joanna Olivas; Aaron Sattler; Roberto A Sánchez-Delgado; Rosa A Maldonado
Journal:  J Biol Inorg Chem       Date:  2013-07-24       Impact factor: 3.358

6.  Antileishmanial and Cytotoxic Activity of Some Highly Oxidized Abietane Diterpenoids from the Bald Cypress, Taxodium distichum.

Authors:  C Benjamin Naman; Anthony D Gromovsky; Cory M Vela; Joshua N Fletcher; Gaurav Gupta; Sanjay Varikuti; Xiaohua Zhu; Emilia M Zywot; Heebyung Chai; Karl A Werbovetz; Abhay R Satoskar; A Douglas Kinghorn
Journal:  J Nat Prod       Date:  2016-02-23       Impact factor: 4.050

7.  Searching for new chemotherapies for tropical diseases: ruthenium-clotrimazole complexes display high in vitro activity against Leishmania major and Trypanosoma cruzi and low toxicity toward normal mammalian cells.

Authors:  Alberto Martínez; Teresia Carreon; Eva Iniguez; Atilio Anzellotti; Antonio Sánchez; Marina Tyan; Aaron Sattler; Linda Herrera; Rosa A Maldonado; Roberto A Sánchez-Delgado
Journal:  J Med Chem       Date:  2012-04-09       Impact factor: 7.446

Review 8.  The (in)visible health risks of climate change.

Authors:  Luke Parry; Claudia Radel; Susana B Adamo; Nigel Clark; Miriam Counterman; Nadia Flores-Yeffal; Diego Pons; Paty Romero-Lankao; Jason Vargo
Journal:  Soc Sci Med       Date:  2019-07-27       Impact factor: 4.634

Review 9.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-11-17

10.  Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.

Authors:  Robert G Schaut; Tara L Grinnage-Pulley; Kevin J Esch; Angela J Toepp; Malcolm S Duthie; Randall F Howard; Steven G Reed; Christine A Petersen
Journal:  Vaccine       Date:  2016-09-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.